On May 5, the Trump Administration issued a pair of executive orders that could signal big changes for the drug industry and health...
Reed Smith LLP
Note: This is Part 1 in a series of blog posts on developments from the U.S. Food and Drug Administration (“FDA”) regarding its...
On May 10, 2022, FDA published draft guidance entitled, “Benefit-Risk Considerations for Product Quality Assessments”, which describes...